Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy by Eggermont, Alexander M M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard;
Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon
M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bastholt, Lars;
Mortier, Laurent; Thomas, Luc; Tahir, Saad; Hauschild, Axel; Hassel, Jessica C; Hodi, F Stephen;
Taitt, Corina; de Pril, Veerle; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro
Abstract: Background On the basis of data from a phase 2 trial that compared the checkpoint inhibitor
ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced
melanoma, this phase 3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had
undergone complete resection of stage III melanoma. Methods After patients had undergone complete
resection of stage III cutaneous melanoma, we randomly assigned them to receive ipilimumab at a dose of
10 mg per kilogram (475 patients) or placebo (476) every 3 weeks for four doses, then every 3 months for
up to 3 years or until disease recurrence or an unacceptable level of toxic effects occurred. Recurrence-free
survival was the primary end point. Secondary end points included overall survival, distant metastasis-
free survival, and safety. Results At a median follow-up of 5.3 years, the 5-year rate of recurrence-free
survival was 40.8% in the ipilimumab group, as compared with 30.3% in the placebo group (hazard ratio
for recurrence or death, 0.76; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). The rate of overall
survival at 5 years was 65.4% in the ipilimumab group, as compared with 54.4% in the placebo group
(hazard ratio for death, 0.72; 95.1% CI, 0.58 to 0.88; P=0.001). The rate of distant metastasis-free
survival at 5 years was 48.3% in the ipilimumab group, as compared with 38.9% in the placebo group
(hazard ratio for death or distant metastasis, 0.76; 95.8% CI, 0.64 to 0.92; P=0.002). Adverse events
of grade 3 or 4 occurred in 54.1% of the patients in the ipilimumab group and in 26.2% of those in
the placebo group. Immune-related adverse events of grade 3 or 4 occurred in 41.6% of the patients in
the ipilimumab group and in 2.7% of those in the placebo group. In the ipilimumab group, 5 patients
(1.1%) died owing to immune-related adverse events. Conclusions As adjuvant therapy for high-risk
stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates
of recurrence-free survival, overall survival, and distant metastasis-free survival than placebo. There
were more immune-related adverse events with ipilimumab than with placebo. (Funded by Bristol-Myers
Squibb; ClinicalTrials.gov number, NCT00636168 , and EudraCT number, 2007-001974-10 .).
DOI: https://doi.org/10.1056/NEJMoa1611299
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-126548
Published Version
Originally published at:
Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok,
Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé,
Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bastholt, Lars; Mortier,
Laurent; Thomas, Luc; Tahir, Saad; Hauschild, Axel; Hassel, Jessica C; Hodi, F Stephen; Taitt, Corina;
de Pril, Veerle; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro (2016). Prolonged survival in
stage III melanoma with ipilimumab adjuvant therapy. New England Journal of Medicine, 375(19):1845-
1855.
DOI: https://doi.org/10.1056/NEJMoa1611299
2
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med nejm.org 1
The authors’ full names, academic de‑
grees, and affiliations are listed in the 
Appendix. Address reprint requests to 
Dr. Eggermont at Gustave Roussy Cancer 
Campus Grand Paris and University Paris–
Sud, 114 Rue Edouard Vaillant, 94805 Ville‑
juif, France, or at  alexander . eggermont@ 
 gustaveroussy . fr.
Drs. Suciu and Testori contributed equal‑
ly to this article.
This article was published on October 8, 
2016, at NEJM.org.
DOI: 10.1056/NEJMoa1611299
Copyright © 2016 Massachusetts Medical Society.
BACKGROUND
On the basis of data from a phase 2 trial that compared the checkpoint inhibitor 
ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in 
patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a 
dose of 10 mg per kilogram in patients who had undergone complete resection of 
stage III melanoma.
METHODS
After patients had undergone complete resection of stage III cutaneous melanoma, 
we randomly assigned them to receive ipilimumab at a dose of 10 mg per kilogram 
(475 patients) or placebo (476) every 3 weeks for four doses, then every 3 months 
for up to 3 years or until disease recurrence or an unacceptable level of toxic ef-
fects occurred. Recurrence-free survival was the primary end point. Secondary end 
points included overall survival, distant metastasis–free survival, and safety.
RESULTS
At a median follow-up of 5.3 years, the 5-year rate of recurrence-free survival was 
40.8% in the ipilimumab group, as compared with 30.3% in the placebo group (hazard 
ratio for recurrence or death, 0.76; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). 
The rate of overall survival at 5 years was 65.4% in the ipilimumab group, as com-
pared with 54.4% in the placebo group (hazard ratio for death, 0.72; 95.1% CI, 
0.58 to 0.88; P = 0.001). The rate of distant metastasis–free survival at 5 years was 
48.3% in the ipilimumab group, as compared with 38.9% in the placebo group 
(hazard ratio for death or distant metastasis, 0.76; 95.8% CI, 0.64 to 0.92; P = 0.002). 
Adverse events of grade 3 or 4 occurred in 54.1% of the patients in the ipilim-
umab group and in 26.2% of those in the placebo group. Immune-related adverse 
events of grade 3 or 4 occurred in 41.6% of the patients in the ipilimumab group 
and in 2.7% of those in the placebo group. In the ipilimumab group, 5 patients (1.1%) 
died owing to immune-related adverse events.
CONCLUSIONS
As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg 
per kilogram resulted in significantly higher rates of recurrence-free survival, overall 
survival, and distant metastasis–free survival than placebo. There were more im-
mune-related adverse events with ipilimumab than with placebo. (Funded by Bristol-
Myers Squibb; ClinicalTrials.gov number, NCT00636168, and EudraCT number, 
2007-001974-10.)
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Ipilimumab, a fully human monoclo-nal antibody that blocks cytotoxic T-lympho-cyte antigen 4 (CTLA-4) to augment antitu-
mor immune responses, was approved by the 
Food and Drug Administration (FDA) and the 
European Medicines Agency in 2011 at a dose of 
3 mg per kilogram of body weight for the treat-
ment of advanced melanoma.1,2 On the basis of 
data from a phase 2 trial that indicated the po-
tential for a dose of 10 mg per kilogram to have 
higher efficacy than the dose of 0.3 mg or 3 mg 
per kilogram in patients with advanced mela-
noma, although at a cost of more toxic effects,3,4 
we conducted a phase 3 trial (European Organi-
zation for Research and Treatment of Cancer 
[EORTC] 18071) of ipilimumab at a dose of 10 mg 
per kilogram in patients who had resected re-
gional lymph node–positive (stage III) melanoma 
with a high risk of recurrence.
The likelihood of systemic metastatic disease 
among patients with stage III melanoma corre-
lates closely with microscopic versus palpable 
nodal disease and with the number of positive 
nodes.5-7 The population of patients with stage III 
melanoma is heterogeneous, with disease-specific 
survival rates of 78% among patients with stage 
IIIA disease, 59% among those with stage IIIB 
disease, and 40% among those with stage IIIC 
disease.5-7 Even within the population of patients 
who have sentinel node–positive cancer, hetero-
geneity is remarkable and correlates closely with 
tumor load in the sentinel node (as defined by 
the Rotterdam criteria; see the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org).8-10 Patients with a metastasis of more 
than 1 mm in the greatest dimension have a sig-
nificantly higher risk of recurrence or death than 
those with a metastasis of 1 mm or less in the 
greatest dimension.8-10
We previously reported the primary results of 
the EORTC 18071 phase 3 trial in which we com-
pared adjuvant ipilimumab with placebo in pa-
tients with resected stage III melanoma.11 At a 
median follow-up of 2.7 years, adjuvant ipilimu-
mab was associated with significantly prolonged 
recurrence-free survival, the primary end point, 
as compared with placebo (hazard ratio, 0.75; 
P = 0.001). The results on the global health scale, 
which was the primary health-related quality-of-
life end point, were not affected by ipilimumab.12 
Approval from the FDA was granted in 2015 on 
the basis of the results of this trial. The effect of 
ipilimumab on overall survival and distant metas-
tasis–free survival is important, given that the only 
other approved systemic therapy in the context of 
adjuvant therapy, interferon alfa, has a marginal 
effect on overall survival.13-15 Here, we report, at a 
median follow-up of 5.3 years, the efficacy of 
adjuvant therapy with ipilimumab on all survival 
end points in patients with high-risk stage III 
melanoma after complete lymph-node dissection.
Me thods
Patients
Eligible patients were 18 years of age or older 
with histologically confirmed cutaneous melano-
ma that was metastatic to regional lymph nodes. 
According to the American Joint Committee on 
Cancer 2009 classification, patients had stage IIIA 
melanoma (patients with N1a cancer [i.e., only one 
node involved with micrometastasis] had to have 
at least one metastasis measuring >1 mm in the 
greatest dimension) or stage IIIB or IIIC melano-
ma with no in-transit metastases (i.e., growing 
>2 cm away from the primary tumor but before 
reaching the nearest lymph node).2 Complete 
regional lymphadenectomy was required within 
12 weeks before randomization. Exclusion crite-
ria included an Eastern Cooperative Oncology 
Group (ECOG) performance-status score of more 
than 1 (on a scale from 0 to 5, with higher num-
bers indicating greater disability), autoimmune 
disease, uncontrolled infection, substantial car-
diovascular disease (New York Heart Association 
functional class III or IV), a lactate dehydrogenase 
level of more than 2 times the upper limit of the 
normal range, use of systemic glucocorticoids, 
and previous systemic therapy for melanoma.
Trial Design and Regimen
In this randomized, double-blind, phase 3 trial, 
patients were enrolled at 99 centers in 19 coun-
tries. Registration was done centrally at the EORTC 
headquarters. A central interactive voice-response 
system was used for randomization and was based 
on a minimization technique.16 Randomization 
was stratified according to disease stage (stage 
IIIA vs. stage IIIB vs. stage IIIC with one, two, or 
three positive nodes vs. stage IIIC with four or 
more positive nodes) and geographic region 
(North America, Europe, or Australia). Local phar-
macists, who were aware of the trial-group assign-
ments, performed the randomization. Clinical in-
vestigators and persons collecting or analyzing the 
data were unaware of the trial-group assignments.
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Patients were randomly assigned in a 1:1 ratio 
to receive an intravenous infusion of ipilimumab 
at a dose of 10 mg per kilogram or placebo every 
3 weeks for four doses, then every 3 months for 
up to 3 years or until disease recurrence, an unac-
ceptable level of toxic effects, a major protocol vio-
lation, or withdrawal of consent (Fig. S1 in the 
Supplementary Appendix). The rules regarding 
the withholding of a dose of ipilimumab or pla-
cebo and the management of immune-related ad-
verse events are detailed in the full trial protocol, 
available at NEJM.org.
The primary end point was recurrence-free 
survival. The secondary end points included over-
all survival, distant metastasis–free survival, safe-
ty, and health-related quality of life.
Assessments
Patients in the two trial groups were assessed for 
recurrence and distant metastases every 3 months 
during the first 3 years and every 6 months there-
after. Physical examination and radiography of 
the chest, computed tomography, magnetic res-
onance imaging, or other imaging techniques 
were performed if indicated. Recurrence or meta-
static lesions had to be histologically confirmed 
whenever possible. The first date when recurrence 
was observed was used in the analysis, regard-
less of the method of assessment.
Recurrence-free survival was defined as the 
time from randomization until the date of first 
recurrence (local, regional, or distant metastasis) 
or death from any cause. Overall survival was 
defined as the time from randomization until 
death from any cause. Distant metastasis–free 
survival was defined as the time from random-
ization until the date of the first distant metas-
tasis or death from any cause.
Data on adverse events were collected for each 
group with the use of the Common Terminology 
Criteria for Adverse Events, version 3.0. Immune-
related adverse events were determined program-
matically from a prespecified list of terms from the 
Medical Dictionary for Regulatory Activities (MedDRA), 
which was updated according to each new ver-
sion of MedDRA.
Resolution of an immune-related adverse event 
of grade 3 or 4 was defined as an improvement 
to grade 1 or less. The grade 3 or 4 event with the 
longest time to resolution was selected for inclu-
sion in the analysis. If the grade 3 or 4 event did 
not resolve, follow-up was censored at the last 
known date that the patient was alive. Similar 
analyses were repeated for immune-related adverse 
events of grade 2 through 5.
Trial Oversight
The trial protocol was approved by the EORTC 
protocol-review committee and by independent 
ethics committees. The trial was conducted in 
accordance with the Declaration of Helsinki and 
with Good Clinical Practice guidelines as defined 
by the International Conference on Harmonisa-
tion. All the patients provided written informed 
consent.
The trial was funded and sponsored by Bristol-
Myers Squibb. The trial was designed by the writ-
ing committee (the trial coordinator [the first 
author], the EORTC headquarters team, and a 
representative of the sponsor). Data were col-
lected and computerized at the EORTC headquar-
ters and were copied to the sponsor after the da-
tabase lock. Data were analyzed independently at 
the EORTC headquarters and by the sponsor. The 
manuscript was written by two of the academic 
authors (the first and penultimate authors), all 
the coauthors commented on it, and editorial as-
sistance was provided by professional medical 
writers paid by the sponsor. The two specified 
academic authors made the decision to submit 
the manuscript for publication, with the consent 
of all the other authors. The authors vouch for 
accuracy and completeness of the data and analy-
ses and confirm the adherence of the trial to the 
protocol.
An independent review committee, whose 
members were unaware of the trial-group as-
signments, assessed disease status and date of re-
currence. An independent data and safety monitor-
ing board assessed the safety and efficacy data 
every 6 months, without formal interim analyses. 
Only at the time of the final analysis of recurrence-
free survival were interim analyses of overall sur-
vival and distant metastasis–free survival per-
formed by an independent statistician, and the 
results were forwarded to members of the data 
and safety monitoring board. On-site source-data 
verification was provided by a clinical research 
organization.
Statistical Analysis
We planned for the trial to include 950 patients. 
In the initial protocol, we calculated that a total 
of 491 deaths would be required in order to pro-
vide the trial with 85% power to detect a difference 
in the 4.5-year overall survival rates of 42.3% in the 
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placebo group and 52.0% in the ipilimumab group, 
corresponding to a hazard ratio for death of 0.76. 
Owing to an improvement in outcomes after re-
currence (because of a change in the treatment 
landscape for patients with melanoma), it was de-
cided, by means of a protocol amendment, to 
perform the final analyses for overall survival 
and distant metastasis–free survival at the same 
time. Given the 506 events of distant metastasis 
or death and 376 deaths at the clinical cutoff date 
(January 31, 2016), it was recomputed (with the 
use of a Lan–DeMets alpha-spending function) 
that the final analyses of overall survival and 
distant metastasis–free survival be performed at 
two-sided alpha levels of 0.049 and 0.042, re-
spectively, so the confidence interval for the 
hazard ratio of the group comparison regarding 
these end points was set at 95.1% and 95.8%, 
respectively; the statistical power was 75.8% and 
89.4%, respectively. The statistical analysis plan 
(available with the trial protocol) indicated that 
in order to preserve the alpha error, a hierarchi-
cal-testing approach would be applied after the 
analysis of the primary end point of recurrence-
free survival. Overall survival was tested first, 
followed by distant metastasis–free survival. For 
the subgroup analysis, the estimated hazard ra-
tio was plotted along with its 99% confidence 
interval.
The main analyses of the efficacy end points 
included all the patients who had undergone 
randomization, according to the intention-to-treat 
principle. The safety profile was assessed in pa-
tients who received at least one dose of the ran-
domly assigned regimen. Details of the statisti-
cal methods are provided in the Supplementary 
Appendix.
R esult s
Patients and Trial Regimen
From July 2008 through August 2011, a total of 
951 patients underwent randomization: 475 pa-
tients were assigned to the ipilimumab group and 
476 to the placebo group. The characteristics at 
baseline were similar between the two random-
ized groups (Table 1).
Six patients (4 patients in the ipilimumab 
group and 2 in the placebo group) did not start 
the randomly assigned regimen (Fig. S2 in the 
Supplementary Appendix). The median number 
of doses that were received was 4 doses (interquar-
tile range, 3 to 8) in the ipilimumab group and 
8 (interquartile range, 4 to 16) in the placebo 
group. At least 1 maintenance dose (dose 5 and 
beyond) was received by 198 of 471 patients 
(42.0%) in the ipilimumab group and by 332 of 
474 (70.0%) in the placebo group.
Of 471 patients who started ipilimumab, 251 
(53.3%) discontinued treatment owing to an ad-
verse event (including 182 patients [38.6%] who 
discontinued within 12 weeks after randomiza-
tion); in 240 patients (51.0%), the event was 
considered by the investigators to be drug-relat-
ed. Among 474 patients who received placebo, 
22 (4.6%) discontinued treatment owing to an 
adverse event. A total of 135 patients (28.7%) in 
the ipilimumab group discontinued treatment 
because of disease recurrence, as compared with 
282 (59.5%) in the placebo group. A total of 63 
patients (13.4%) in the ipilimumab group and 
143 (30.2%) in the placebo group completed the 
3-year treatment period (Fig. S2 in the Supple-
mentary Appendix).
The overall median follow-up was 5.3 years. 
The median follow-up was 5.3 years in the ipilim-
umab group and 5.4 years in the placebo group.
Efficacy and Postprotocol Treatment
In this updated analysis, the rate of recurrence-
free survival at 5 years was 40.8% in the ipilim-
umab group, as compared with 30.3% in the pla-
cebo group (hazard ratio for recurrence or death, 
0.76; 95% confidence interval [CI], 0.64 to 0.89; 
P<0.001) (Fig. 1A). The overall significant pro-
longation of recurrence-free survival that was 
due to adjuvant ipilimumab appeared to be con-
sistent across subgroups (Fig. S3A in the Supple-
mentary Appendix), but the trial was not powered 
to provide robust subgroup analysis. Ipilimumab 
appeared to be helpful in patients with micro-
scopic involvement (hazard ratio vs. placebo, 0.68) 
and in patients with macroscopic involvement 
(hazard ratio, 0.84) (Fig. S3B and S3C in the Sup-
plementary Appendix).
Among the 264 patients in the ipilimumab 
group who had recurrence or died, 194 had re-
ceived at least one postprotocol treatment (Ta-
ble 2). These treatments included ipilimumab 
(24 patients), anti–programmed death 1 (PD-1) 
therapy (24 patients), and a BRAF inhibitor (63 
patients). Among the 323 patients in the placebo 
group who had recurrence or died, 250 received 
postprotocol treatment: ipilimumab (76 patients), 
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anti–PD-1 therapy (30 patients), and a BRAF in-
hibitor (88 patients). Overall survival after disease 
recurrence was similar in the two trial groups 
(hazard ratio for ipilimumab vs. placebo, 0.89), 
which suggests that the difference in recurrence-
free survival would persist in terms of overall 
survival.
The overall survival rate at 5 years was 65.4% 
(95% CI, 60.8 to 69.6) in the ipilimumab group, 
as compared with 54.4% (95% CI, 49.7 to 58.9) 
in the placebo group. Overall survival was sig-
nificantly longer in the ipilimumab group than 
in the placebo group (hazard ratio for death from 
any cause, 0.72; 95.1% CI, 0.58 to 0.88; P = 0.001) 
(Fig. 1B). The prolongation of overall survival with 
ipilimumab was generally consistent across sub-
Characteristic
Ipilimumab 
(N = 475)
Placebo 
(N = 476)
Sex — no. (%)
Male 296 (62.3) 293 (61.6)
Female 179 (37.7) 183 (38.4)
Age
Median (range) — yr 51 (20–84) 52 (18–78)
Distribution — no. (%)
<50 yr 214 (45.1) 211 (44.3)
51 to <65 yr 180 (37.9) 178 (37.4)
≥65 yr 81 (17.1) 87 (18.3)
Disease stage — no. (%)
At randomization
IIIA 98 (20.6) 98 (20.6)
IIIB 182 (38.3) 182 (38.2)
IIIC with 1–3 positive lymph nodes 122 (25.7) 121 (25.4)
IIIC with ≥4 positive lymph nodes 73 (15.4) 75 (15.8)
According to AJCC 2002 criteria†
IIIA 98 (20.6) 88 (18.5)
IIIB 213 (44.8) 207 (43.5)
IIIC with 1–3 positive lymph nodes 69 (14.5) 83 (17.4)
IIIC with ≥4 positive lymph nodes 95 (20.0) 98 (20.6)
Type of lymph‑node involvement — no. (%)†
Microscopic 210 (44.2) 193 (40.5)
Macroscopic 265 (55.8) 283 (59.5)
No. of positive lymph nodes on pathological testing — no. (%)†
1 217 (45.7) 220 (46.2)
2 or 3 163 (34.3) 158 (33.2)
≥4 95 (20.0) 98 (20.6)
Ulceration — no. (%)†
Yes 197 (41.5) 203 (42.6)
No 257 (54.1) 244 (51.3)
Unknown 21 (4.4) 29 (6.1)
*  There were no significant between‑group differences in the characteristics listed here. Percentages may not total 100 
because of rounding. AJCC denotes American Joint Committee on Cancer.
†  Data were from case‑report forms.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
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groups (Fig. 2, and Fig. S4 in the Supplementary 
Appendix). The rate of distant metastasis–free 
survival at 5 years was higher in the ipilimumab 
group than in the placebo group (48.3% vs. 38.9%; 
hazard ratio for distant metastasis or death, 
0.76; 95.8% CI, 0.64 to 0.92; P = 0.002) (Fig. 2C).
Safety
Among the 471 patients who received ipilimumab, 
465 (98.7%) had an adverse event of any grade, 
with grade 3 or 4 adverse events occurring in 255 
patients (54.1%); among the 474 patients who re-
ceived placebo, 432 (91.1%) had an adverse event 
of any grade, with grade 3 or 4 adverse events 
occurring in 124 (26.2%) (Table S1 in the Sup-
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Figure 1. Kaplan–Meier Estimates of Recurrence-free 
Survival (RFS), Overall Survival, and Distant Metastasis–
free Survival (DMFS).
Panel A shows the Kaplan–Meier estimate of recur‑
rence‑free survival according to the independent re‑
view committee. In the ipilimumab group, local or re‑
gional recurrence was reported in 96 patients, distant 
metastasis or death due to melanoma in 157, and 
death due to another cause or an unknown cause in 
11. In the placebo group, local or regional recurrence 
was reported in 114 patients, distant metastasis or 
death due to melanoma in 204, and death due to an‑
other cause or an unknown cause in 5. All the statisti‑
cal comparisons shown here were stratified according 
to the disease stage as provided at randomization. In 
the comparison that was stratified according to the 
disease stage as given on case‑report forms, the haz‑
ard ratio for recurrence or death was 0.77 (95% CI, 
0.65 to 0.90; P = 0.001). In a per‑protocol analysis of 
the comparison that was stratified according to the 
disease stage as given at randomization, the hazard 
ratio was 0.77 (95% CI, 0.65 to 0.91; P = 0.002). Panel 
B shows the Kaplan–Meier estimate of overall surviv‑
al. Because the number of patients with a follow‑up of 
more than 7 years was too small, the estimated medi‑
an overall survival was either unreliable or not reached. 
In the comparison that was stratified according to the 
disease stage as given on case‑report forms, the haz‑
ard ratio for death was 0.73 (95.1% CI, 0.60 to 0.90; 
P = 0.003). In a per‑protocol analysis of the compari‑
son stratified according to the disease stage as given 
at randomization, the hazard ratio was 0.72 (95.1% CI, 
0.58 to 0.89; P = 0.002). Panel C shows the Kaplan–
Meier estimate of distant metastasis–free survival ac‑
cording to the independent review committee. In the 
comparison that was stratified according to the dis‑
ease stage as given on the case‑report forms, the haz‑
ard ratio for distant metastasis or death was 0.77 
(95.8% CI, 0.65 to 0.93; P = 0.004). In a per‑protocol 
analysis of the comparison stratified according to the 
disease stage as given at randomization, the hazard 
ratio was 0.76 (95.8% CI, 0.63 to 0.91; P = 0.003).
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plementary Appendix). Immune-related adverse 
events during the trial were more frequent with 
ipilimumab than with placebo (Table 3). Immune-
related adverse events of grade 3 or 4 occurred in 
41.6% of the patients in the ipilimumab group 
and in 2.7% of those in the placebo group. The 
most common immune-related adverse events of 
grade 3 or 4 in the ipilimumab group were gas-
trointestinal (in 16.1% of the patients), hepatic 
(in 10.8%), and endocrine (in 7.9%). The median 
time to the onset of immune-related adverse 
events of grade 2 through 5 during the trial 
ranged from 4.0 weeks (skin immune-related ad-
verse events) to 13.1 weeks (neurologic immune-
related adverse events) (Table S2 in the Supple-
mentary Appendix). Endocrine immune-related 
adverse events of grade 2 through 5 resolved in 
51.5% of the patients, and the median time to 
resolution was 54.3 weeks. The majority (82 to 
97%) of all other immune-related adverse events 
of grade 2, 3, or 4 resolved, and the median time 
to resolution ranged from 4.0 to 8.0 weeks.
Five patients (1.1%) died owing to adverse 
events that were attributed to ipilimumab: three 
patients died from colitis (two patients with in-
testinal perforation), one patient from myocardi-
tis, and one patient from multiorgan failure that 
was associated with the Guillain–Barré syndrome. 
These deaths occurred before the start of main-
tenance therapy. Of these patients, four had re-
ceived glucocorticoids and one anti–tumor ne-
crosis factor antibodies.
Discussion
In this randomized, phase 3 trial involving pa-
tients with resected, high-risk stage III melano-
ma, ipilimumab at a dose of 10 mg per kilogram 
significantly prolonged overall survival and dis-
tant metastasis–free survival as compared with 
placebo. The risk of death was 28% lower with 
ipilimumab than with placebo, and the risk of 
distant metastasis or death was lower by 24%. At 
5 years, ipilimumab treatment was associated 
with rates that were approximately 10 percent-
age points higher than the rates with placebo for 
all end points: recurrence-free survival (40.8% vs. 
30.3%), overall survival (65.4% vs. 54.4%), and 
distant metastasis–free survival (48.3% vs. 38.9%). 
The results show that at the cost of substantial 
toxic effects, the previously observed prolonga-
tion of recurrence-free survival with ipilimumab 
Treatment All Patients
Patients Who Had Disease Recurrence 
or Died
Ipilimumab 
(N = 475)
Placebo 
(N = 476)
Ipilimumab 
(N = 264)
Placebo 
(N = 323)
number (percent)
First postprotocol treatment
Chemotherapy 41 (8.6) 53 (11.1) 40 (15.2) 52 (16.1)
Radiotherapy 19 (4.0) 19 (4.0) 19 (7.2) 19 (5.9)
Surgery 47 (9.9) 33 (6.9) 41 (15.5) 31 (9.6)
Chemoradiotherapy 1 (0.2) 4 (0.8) 1 (0.4) 4 (1.2)
Biologic‑response modifier 48 (10.1) 88 (18.5) 48 (18.2) 86 (26.6)
Combination therapy 13 (2.7) 22 (4.6) 12 (4.5) 22 (6.8)
Other 37 (7.8) 36 (7.6) 33 (12.5) 36 (11.1)
No treatment reported 269 (56.6) 221 (46.4) 70 (26.5) 73 (22.6)
Ipilimumab 24 (5.1) 76 (16.0) 24 (9.1) 76 (23.5)
Anti–PD‑1 agent 25 (5.3) 30 (6.3) 24 (9.1) 30 (9.3)
BRAF inhibitor 65 (13.7) 88 (18.5) 63 (23.9) 88 (27.2)
*  Percentages may not total 100 because of rounding. PD‑1 denotes programmed death 1.
Table 2. Postprotocol Treatment in All the Patients Who Underwent Randomization and in Those Who Had Disease 
Recurrence or Died.*
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is confirmed in the current updated analysis and 
that it translated into a prolongation in overall 
survival and distant metastasis–free survival.
Despite successful treatment with surgery (fol-
lowed by adjuvant therapy in patients at high risk 
for disease recurrence), only approximately 45% 
of patients with stage III melanoma will be dis-
ease-free after 4 years; less than 40% of patients 
who have surgery alone will be disease-free after 
4 years.17 Interferon alfa is currently approved in 
both the United States and the European Union 
for the treatment of stage III melanoma after 
surgery. In a literature-based meta-analysis of 17 
randomized, controlled trials involving 8122 pa-
tients with high-risk cutaneous melanoma, inter-
feron alfa prolonged the time to recurrence (haz-
ard ratio for disease recurrence with interferon 
alfa vs. observation, 0.82).15 Owing to the mar-
ginal benefit in overall survival (hazard ratio for 
death, 0.89) and the considerable toxic effects, 
interferon alfa is not widely used as an adjuvant 
therapy.18 Although the benefit–risk profile of in-
terferon alfa as compared with ipilimumab re-
mains unclear, a phase 3 trial (ECOG 1609) that 
directly compares interferon alfa with ipilimumab 
at a dose of 3 or 10 mg per kilogram in patients 
with resected stage III or IV melanoma is ongo-
ing (ClinicalTrials.gov number, NCT01274338). 
In our trial (EORTC 18071), patients were treated 
for up to 3 years, but only 13.4% of the patients 
completed this treatment period and 40% had 
stopped ipilimumab treatment at the end of the 
Figure 2. Forest Plot for Overall Survival, According to Trial Group.
Results are expressed as unstratified hazard ratios for the risk of death in the ipilimumab group as compared with the placebo group 
with 95% confidence intervals for the analysis of the total group and with 99% confidence intervals for all the subgroup analyses. The 
size of the box is proportional to the total number of deaths reported in each subgroup, the diamond is centered on the overall hazard 
ratio for death and covers its 95% confidence interval, and the dashed line represents the overall hazard ratio for death. The P value for 
the univariate analysis that included all patients was provided by the unstratified log‑rank test. The P value for the analysis of heteroge‑
neity between the hazard ratios computed within the subgroups of a given variable was provided by the test of heterogeneity (see the 
Supplementary Appendix). The disease stage, according to the case‑report forms, was determined with the use of the American Joint 
Committee on Cancer 2002 criteria. The number of positive lymph nodes was determined by means of pathological testing. Additional 
information is provided in Figure S4A in the Supplementary Appendix.
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first four doses over the first 3 months. Thus, 
the EORTC 18071 trial cannot address whether 
maintenance treatment is necessary.
In the current trial, the survival benefit of 
ipilimumab over placebo was generally consistent 
across subgroups. This benefit was observed not 
only in patients with microscopic involvement 
only (sentinel node–positive) but also in patients 
with macroscopic or palpable nodes. In contrast, 
in previous EORTC trials of adjuvant therapy in 
patients with melanoma,17,19-22 a significant ben-
efit with interferon alfa was observed only in 
patients with microscopic involvement. Similarly, 
in contrast to interferon alfa, for which ulceration 
is the overriding determinant of activity,13,17,20-23 
ipilimumab prolonged survival among patients 
with nonulcerated melanoma and among those 
with ulcerated melanoma.
The rate of adverse events with ipilimumab in 
the context of adjuvant therapy was substantial 
and led to the discontinuation of treatment in 
approximately 40% of the patients by the end of 
the initial dosing period (i.e., before maintenance 
therapy). This frequency is higher than that ob-
served with the same dose in the pooled analysis 
involving patients with advanced melanoma.2-4 The 
vast majority of immune-related adverse events of 
grade 2, 3, or 4 resolved within 4 to 8 weeks 
with the use of established management guide-
lines. However, for endocrinopathies, the medi-
an time to resolution was 54 weeks, and 48.5% 
of the patients who had endocrinopathy continue 
to take hormone-replacement therapies. In this 
trial, adjuvant therapy with ipilimumab was as-
sociated with a higher risk and greater degree of 
diarrhea, insomnia, and fatigue than placebo dur-
ing the induction period, but ipilimumab did not 
have a negative effect on the global health scale 
of health-related quality of life.12
Of concern are the five patients (1.1%) in the 
ipilimumab group who died owing to drug-relat-
ed adverse events. In the context of adjuvant 
therapy, the benefit–risk profile is particularly 
important in view of the prognostic heterogeneity 
observed in patients with stage III melanoma.
In conclusion, adjuvant ipilimumab was as-
Event Ipilimumab (N = 471) Placebo (N = 474)
Any Grade Grade 3 Grade 4 Grade 5 Any Grade Grade 3 Grade 4 Grade 5
Any immune‑related adverse 
event
426 (90.4) 169 (35.9) 27 (5.7) 5 (1.1) 188 (39.7) 12 (2.5) 1 (0.2) 0
Any dermatologic event 298 (63.3) 20 (4.2) 0 0 99 (20.9) 0 0 0
Rash 161 (34.2) 5 (1.1) 0 0 52 (11.0) 0 0 0
Any gastrointestinal event† 217 (46.1) 70 (14.9) 6 (1.3) 3 (0.6) 85 (17.9) 3 (0.6) 1 (0.2) 0
Diarrhea 194 (41.2) 46 (9.8) 0 0 80 (16.9) 2 (0.4) 0 0
Colitis 73 (15.5) 32 (6.8) 4 (0.8) 3 (0.6) 7 (1.5) 1 (0.2) 1 (0.2) 0
Any endocrine‑system event 178 (37.8) 34 (7.2) 3 (0.6) 0 38 (8.0) 1 (0.2) 0 0
Hypophysitis 77 (16.3) 20 (4.2) 1 (0.2) 0 1 (0.2) 0 0 0
Any hepatic event 115 (24.4) 38 (8.1) 13 (2.8) 0 20 (4.2) 1 (0.2) 0 0
Increase in liver‑enzyme 
levels
83 (17.6) 14 (3.0) 6 (1.3) 0 18 (3.8) 0 0 0
Any neurologic event 21 (4.5) 5 (1.1) 4 (0.8) 0 9 (1.9) 0 0 0
Other‡ 111 (23.6) 34 (7.2) 2 (0.4) 2 (0.4) 23 (4.9) 8 (1.7) 0 0
*  The safety analysis included all the patients who underwent randomization and received at least one dose of ipilimumab or placebo (945 pa‑
tients). Immune‑related adverse events that occurred in at least 10% of the patients are reported. Patients may have had more than one 
event. In the ipilimumab group, 5 patients died because of drug‑related adverse events; 3 patients died from colitis (2 patients with gastro‑
intestinal perforation), 1 from myocarditis, and 1 from multiorgan failure associated with the Guillain–Barré syndrome.
†  Gastrointestinal perforation occurred in seven patients (1.5%) in the ipilimumab group (all such events were considered to be related to ipi‑
limumab) and in three patients (0.6%) in the placebo group (none of these events were considered to be related to placebo).
‡  In the ipilimumab group, 26 patients had a grade 3 or 4 lipase level, 4 had a grade 3 or 4 immune‑system disorder (hypersensitivity, autoim‑
mune disorder, anaphylactoid reaction, or drug hypersensitivity), 4 had grade 3 lung infiltration, pneumonitis, or interstitial lung disease,  
1 had arthritis, and 1 had uveitis.
Table 3. Immune-Related Adverse Events.*
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sociated with clinical improvements and signifi-
cantly prolonged overall survival and distant me-
tastasis–free survival, as compared with placebo, 
among patients with high-risk stage III melanoma, 
thus extending previous findings of a prolonga-
tion of recurrence-free survival. Adverse events 
were common but mostly transient. Some adverse 
events were serious, and even death from treat-
ment occurred despite the use of established treat-
ment algorithms.
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